SMALL ANIMAL IGRT SPECIAL FEATURE: SHORT COMMUNICATION

MRI-guided radiotherapy of the SK-N-SH neuroblastoma xenograft model using a small animal radiation research platform

AURÉLIEN CORROYER-DULMONT, PhD, NADIA FALZONE, PhD, VEERLE KERSEMANS, PhD, JAMES THOMPSON, PhD, MARK HILL, PhD, DANNY ALLEN, PhD, JOHN BEECH, PhD, STUART GILCHRIST, MSc, PAUL KINCHESH, PhD, BORIS VOJNOVIC, PhD, IAIN TULLIS, PhD, MARK N GAZE, MB BS, MD, SEAN SMART, PhD and KATHERINE A VALLIS, MB BS, PhD

1CR-UK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK
2University College London Hospitals NHS Foundation Trust, London, UK

Address correspondence to: Professor Katherine A Vallis
E-mail: katherine.vallis@oncology.ox.ac.uk

Objective: Neuroblastoma has one of the lowest survival rates of all childhood cancers, despite the use of intensive treatment regimens. Preclinical models of neuroblastoma are essential for testing new multimodality protocols, including those that involve radiotherapy (RT). The aim of this study was to develop a robust method for RT planning and tumour response monitoring based on combined MRI and cone-beam CT (CBCT) imaging and to apply it to a widely studied mouse xenograft model of neuroblastoma, SK-N-SH.

Methods: As part of a tumour growth inhibition study, SK-N-SH xenografts were generated in BALB/c nu/nu mice. Mice (n = 8) were placed in a printed MR- and CT-compatible plastic cradle, imaged using a 4.7-T MRI scanner and then transferred to a small animal radiation research platform (SARRP) irradiator with on-board CBCT. MRI/CBCT co-registration was performed to enable RT planning using the soft-tissue contrast afforded by MRI prior to delivery of RT (5 Gy). Tumour response was assessed by serial MRI and calliper measurements.

Results: SK-N-SH xenografts formed soft, deformable tumours that could not be differentiated from surrounding normal tissues using CBCT. MR images, which allowed clear delineation of tumours, were successfully co-registered with CBCT images, allowing conformal RT to be delivered. MRI measurements of tumour volume 4 days after RT correlated strongly with length of survival time.

Conclusion: MRI allowed precision RT of SK-N-SH tumours and provided an accurate means of measuring tumour response.

Advances in knowledge: MRI-based RT planning of murine tumours is feasible using an SARRP irradiator.

INTRODUCTION

Neuroblastoma is the most frequent extracranial tumour in infants and young children. The treatment of high-risk neuroblastoma usually consists of some mix of surgery, chemotherapy, radiotherapy (RT), stem cell transplant, immunotherapy and retinoid therapy. However, because at 40%, the 4-year overall survival for late-stage neuroblastoma is still low compared with other childhood malignancies, new combination regimens are being developed and tested. In some cases, it is desirable to test investigational protocols in preclinical models of the disease to establish efficacy. Xenograft mouse models are frequently used to study the effects of anticancer drugs and RT in vivo, and the SK-N-SH human neuroblastoma model has been widely studied for this purpose. The aim of this short communication was to present a method for MRI-guided RT of SK-N-SH xenografts and to track post-treatment changes using MRI and using techniques previously developed for the delivery of RT to pancreatic tumours. This method development study involved eight mice that were a subgroup of animals used in a larger therapy study (to be reported separately).

METHODS AND MATERIALS

Cell line
The SK-N-SH human neuroblastoma cell line was obtained from American Type Culture Collections (ATCC, Manassas, VA) and cultured in Dulbecco’s Modified Eagle Medium (DMEM: Sigma Aldrich, UK) supplemented with 10% foetal calf serum (Invitrogen, UK), 2-mM glutamine (Sigma–Aldrich, UK) and 100-U ml⁻¹ penicillin/streptomycin (Invitrogen, UK).

Mouse neuroblastoma model
All animal procedures were carried out in accordance with the UK Animals (Scientific Procedures) Act 1986 and with
the local ethics committee approval. In preliminary experiments, the frequency of tumour development following subcutaneous injection of SK-N-SH cells into the flanks of nude athymic mice (BALB/c nu/nu) was found to be low (10%). Therefore, SK-N-SH cells (5 × 10^6) in 100 μl of matrigel were injected subcutaneously into the flanks of non-obese diabetic/severe combined immunodeficiency mice (20–25 g, 8 weeks old, female, Charles River, UK). In this mouse strain, which is profoundly immunodeficient and is therefore an excellent recipient for engrafted human cells, the success rate of xenograft development was 100%. Tumours were excised and homogenized when they reached a geometric mean diameter of 10 mm (at approximately 5 weeks). Tumour homogenates were then injected into the right flank of recipient BALB/c nu/nu mice (15–20 g, 8 weeks old, female, Charles River, UK). Following this procedure, the proportion of BALB/c nu/nu mice that developed xenograft tumours was 100%. A common method to assess tumour volume is to measure the two longest perpendicular axes in the x–y plane using callipers and then the depth is assumed to be equivalent to the shortest of the perpendicular axes. However, SK-N-SH xenografts were flat in shape and easily deformable and it was not possible to obtain accurate volume measurements using this method. Therefore, in this study, when using callipers, tumour size was reported as the maximum tumour diameter. Animals were entered into study when their tumour volume reached 500 mm^3 as measured by MRI. Figure 1 shows a summary of the timing of imaging events and treatment.

Radiotherapy

Animals were entered into the study when their tumour volume reached 500 mm^3 (at about 7 weeks after inoculation of SK-N-SH cells) and were randomly assigned to two groups: control (no treatment) or external beam RT. RT treatment (220-kVp X-rays; half-value layer of 0.93 mmCu) was administered using the SARRP irradiator at a dose rate of 2 Gy min^-1 using a range of custom collimators depending on the tumour geometry. Dosimetry was performed using an EBT3 film (Ashland ISP Advanced Materials, Wayne, NJ) that was calibrated against absolute measurements determined by following the recommendations of the report of the American Association of Physicists in Medicine Task Group 61.3 On transfer from the MR scanner to the irradiator, MR images were imported into the SARRP system (Figure 3b). MR images were co-registered with the SARRP-CBCT image using an in-house MATLAB®

Figure 2. (a) Cone-beam CT (CBCT) and (b) MR whole-body images of a representative SK-N-SH xenograft-bearing mouse. The tumour is outlined in yellow on the MR image but is not visible on the CBCT image.
code based on the modality independent neighbourhood descriptor algorithm for multimodal deformable registration.6 The resulting MR images were then imported into the Muriplan software (Xstrahl Ltd, Camberly, UK), allowing the target volume to be clearly identified, enabling optimal beam delivery (Figure 3b). A single fraction of 5 Gy was delivered which, based on published data, was predicted to give a robust tumour response in this model.7 The time from MRI acquisition to the end of the RT delivery was approximately 20 min. To monitor tumour response to RT, eight mice (three controls; five in RT group) were imaged weekly using MRI. Mice were euthanized when the tumour volume reached 800 mm³.

Image processing and analysis
Image analysis was performed using ImageJ (National Institutes of Health, Bethesda, MD) software. Tumour volume delineation was performed manually on all adjacent $T_2$ weighted slices. The tumour volume was calculated by multiplying the area of the tumour on each slice by the slice thickness and then adding these together.

Statistical analyses
All data are presented as mean ± standard deviation. One-way analysis of variance followed by Tukey’s post hoc test was used to assess differences in tumour volume between groups. A log-rank test was used to compare Kaplan–Meier curves. Statistical analyses were obtained with GraphPad Prism® software (GraphPad Software, Inc., La Jolla, CA).

RESULTS
Serial MRI was performed to assess tumour response to RT and compared with calliper measurements. On Day 0 (before

Figure 3. MRI-guided RT protocol: (a) the cradle positions on the MRI scanner (left) and small animal radiation research platform (SARRP) (right). (b) The radiotherapy (RT) protocol involves MRI anatomical whole-body image acquisition, followed by CBCT whole-body acquisition, MATLAB® (MathWorks®, Natick, MA) rigid co-registration and target volume planning using anatomical information from MRI and Muriplan software.
treatment), the tumour volume, as assessed by MRI or calliper measurements, was similar in the control and RT groups (Figure 4a,d). At 4 and 6 days following treatment, MR images showed a marked decrease in the tumour volume in the RT vs control groups (Figure 4b,c). Interestingly, it was found that the change in tumour size at 4 days was not detected by calliper measurements \((p = 0.14)\) but was apparent using MRI assessment \((p < 0.001)\) (Figure 4c). The treatment effect became observable with calliper assessment only from Day 6 \((p < 0.01)\) (Figure 4f).

Serial MRI and calliper measurements of tumour size were performed to assess the ability of the two methods to detect tumour progression. After an initial decrease in tumour volume, tumour regrowth was observed from 8 days after RT with MRI (Figure 5a). However, expansion of tumour volume was not detected by calliper assessment until Day 17. There was a significant increase in survival time in the RT group compared with the control group \((p < 0.01)\) (Figure 5b). These survival data were used to evaluate the ability of both methods (MRI and calliper) to predict the overall survival at an early time point (4 days) after RT (Figure 5c,d). However, the tumour volume derived from MR images at 4 days did correlate strongly with survival \((R^2 = 0.82 \text{ and } p < 0.01)\) (Figure 5c).

**DISCUSSION**

The SK-N-SH cell line is a preclinical model of human neuroblastoma that has been used extensively to generate xenograft tumours in mice. However, the implanted SK-N-SH cells do not form firm, well-defined masses. This presents a problem when treating tumours with external radiation, as it is difficult to define the extent of tumour infiltration, potentially increasing the risk of irradiating adjacent normal tissues or missing tumours. This is relevant to high-risk neuroblastoma in children, since it forms poorly margined, infiltrative tumours that often lie in close proximity to radiosensitive organs such as the intra-abdominal viscera, lungs and spinal cord. To address this problem, we developed an MR-guided RT protocol using an in-house consecutive MRI-SARRP protocol. A purpose-built, plastic cradle that allows MRI and CBCT co-registration was designed and constructed. The cradle facilitated MATLAB® co-registration of MR and CBCT images, allowing the RT target volume to be planned directly on the anatomical MR image. Our results concurred with those of Bolcaen et al., who showed that MRI was superior to CBCT for the delineation of the tumour volume prior to RT in a preclinical brain tumour model. Furthermore, this approach led to a significant normal tissue dose decrease during RT.

In the present study, measurement by calliper, a common method for the evaluation of xenograft size, was not sufficiently

---

**Figure 4.** Response of SK-N-SH tumours to radiotherapy (RT) measured using MRI and callipers: representative MR images of control (left) and RT-treated (right) tumours at (a) Day 0 (before treatment), (b) 4 days and (c) 6 days after RT. Tumours are outlined in yellow. Bar charts show tumour volume measured by MRI and maximum tumour diameter measured by calliper at (d) Day 0 (before treatment), (e) 4 days and (f) 6 days after RT (Mean ± standard deviation). ***\(p < 0.001\) and **\(p < 0.01\), RT vs control group.
sensitive to detect early tumour regrowth and measurements at early time points did not correlate with survival time. This is partly owing to the physical characteristics of SK-N-SH xenografts, as they from flattened, poorly defined tumours in nude mice, making them difficult to measure by calliper (Figure 2b). In contrast, anatomical MRI assessment of tumour volume provided insight into the early effects of treatment and correlated with length of survival time. The utility of other imaging modalities to detect tumour response has been investigated. For example, Valentiner et al9 demonstrated the advantages of using 18F-fluorothymidine (FLT) positron emission tomography (PET) compared with 18F-fluorodeoxyglucose PET for tumour detection in the SK-N-SH model. Robust methods to plan and assess RT efficacy in this preclinical model is vitally important for the evaluation of new therapeutic approaches: for example, protocols that combine RT with chemotherapy and radionuclide therapy.10

CONCLUSION
An MRI-guided RT protocol for the treatment of a widely used human neuroblastoma model has been developed. MRI provides accurate monitoring of tumour volume, thereby facilitating the early detection of the RT treatment effect and its predictive value on overall survival.

FUNDING
This work was supported through the CR-UK/MRC Oxford Institute for Radiation Oncology and the CR-UK/EPSRC Oxford Cancer Imaging Centre. MNG is supported by the NIHR University College London Hospitals Biomedical Research Centre.

REFERENCES

1. Gains J, Mandeville H, Cork N, Brock P, Gaze M. Ten challenges in the management of neuroblastoma. Future Oncol 2012; 8: 839–58. doi: https://doi.org/10.2217/fon.12.70
2. Pinto NR, Applebaum MA, Volchenboum SL, Matthey KK, London WB, Ambros PF, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol 2015; 33: 3008–17. doi: https://doi.org/10.1200/JCO.2014.59.4648
3. Schwankhaus N, Gathmann C, Wicklein D, Riecken K, Schumacher U, Valentiner U. Cell adhesion molecules in metastatic neuroblastoma models. Clin Exp Metastasis 2014; 31: 483–96. doi: https://doi.org/10.1007/s10585-014-9643-8
4. Beech J, Allen D, Thompson J, Gilchrist S, Kinchesh P, Newman R, et al. MR-guided...
radiotherapy planning in the mouse abdomen. *Magma* 2015; **28**: S366.

5. Ma CM, Coffey CW, DeWerd LA, Liu C, Nath R, Seltzer SM, et al. AAPM protocol for 40–300 kV X-ray beam dosimetry in radiotherapy and radiobiology. *Med Phys* 2001; **28**: 868–93. doi: [https://doi.org/10.1118/1.1374247](https://doi.org/10.1118/1.1374247)

6. Heinrich MP, Jenkinson M, Bhushan M, Matin T, Gleson FV, Brady SM, et al. MIND: modality independent neighbourhood descriptor for multi-modal deformable registration. *Med Image Anal* 2012; **16**: 1423–35. doi: [https://doi.org/10.1016/j.media.2012.05.008](https://doi.org/10.1016/j.media.2012.05.008)

7. Rutgers M, Buitenhuys CK, Hoefnagel CA, Voune PA, Smets LA. Targeting of meta-iodobenzylguanidine to SK-N-SH human neuroblastoma xenografts: tissue distribution, metabolism and therapeutic efficacy. *Int J Cancer* 2000; **87**: 412–22. doi: [https://doi.org/10.1002/(SICI)1097-0215(20000801)87:3<412::AID-IJC16>3.0.CO;2-X](https://doi.org/10.1002/(SICI)1097-0215(20000801)87:3<412::AID-IJC16>3.0.CO;2-X)

8. Bolcaen J, Descamps B, Deblaere K, Boterberg T, Hallaert G, Van den Broecke C, et al. MRI-guided 3D conformal arc micro-irradiation of a F98 glioblastoma rat model using the small animal radiation research platform (SARRP). *J Neurooncol* 2014; **120**: 257–66. doi: [https://doi.org/10.1007/s11060-014-1552-9](https://doi.org/10.1007/s11060-014-1552-9)

9. Valentiner U, Haane C, Peldschus K, Gustke H, Brenner W, Wilke F, et al. [18F]FDG and [18F]FLT PET-CT and MR imaging of human neuroblastomas in a SCID mouse xenograft model. *Anticancer Res* 2008; **28**: 2561–8.

10. Dietrich A, Koi L, Zopel K, Siilver W, Kotzerke J, Baumann M, et al. Improving external beam radiotherapy by combination with internal irradiation. *Br J Radiol* 2015; **88**: 20150042. doi: [https://doi.org/10.1259/brj.20150042](https://doi.org/10.1259/brj.20150042)